CLVT — Clarivate Plc

Summary of Clarivate Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $586 million, reflecting a modest increase driven by organic growth and favorable foreign exchange impacts.
• Organic ACV Growth: 1.6%, with subscription organic revenue growth at 1.7%.
• Adjusted EBITDA: $241 million, a 41% margin, up nearly 200 basis points year-over-year.
• Net Loss: $40 million, an improvement of $64 million from the previous year due to foreign exchange benefits and reduced expenses.
• Adjusted Diluted EPS: Increased by nearly 30% to $0.18.
• Free Cash Flow: Approximately $79 million, used to retire $143 million of debt.

2. Strategic Updates and Business Highlights

• Value Creation Plan: Progress is evident across all four pillars: business model optimization, improved sales execution, AI innovation, and portfolio rationalization.
• Subscription Model: Strong adoption of subscription-based solutions, with over 600 new subscriptions sold in the past year.
• AI Integration: Significant investment in AI capabilities, leading to operational efficiencies and enhanced product offerings, such as the collaboration with Anthropic for AI integration.
• Geographic Expansion: Notable growth in China, particularly in the Academic & Government segment, with several key wins.
• Intellectual Property Segment: Improvement in renewal rates and sales execution, with a focus on major contracts with national IP offices.

3. Forward Guidance and Outlook

• Full Year Guidance: Reaffirmed with expected organic ACV growth of 2-3% and recurring organic growth of about 1.5%.
• Revenue Projection: Anticipated decline of approximately $100 million due to business disposals, with total revenue expected to reach $2.36 billion.
• Adjusted EBITDA Margin: Expected to increase to nearly 43%.
• Free Cash Flow: Projected to grow by about 10% to $400 million.

4. Bad News, Challenges, or Points of Concern

• Net Loss: Despite improvements, the company reported a net loss of $40 million.
• Transactional Revenue Decline: Transactional revenues were down, particularly in the Academic & Government segment, attributed to timing issues in software implementations.
• Life Sciences & Healthcare Business: The segment remains heavily transactional, which poses challenges for achieving a higher recurring revenue mix.
• Competitive Pressures: Increased competition in AI capabilities from other firms, necessitating ongoing innovation and differentiation.

5. Notable Q&A Insights

• AI Product Reception: Positive feedback on AI innovations, with significant efficiency gains reported by customers.
• Competitive Landscape: Clarivate is recognized as a leader in AI innovation within the academic ecosystem, with strong adoption rates.
• China Market Potential: The company sees significant opportunities for growth in China across various segments, particularly in Academic & Government.
• Intellectual Property Segment Outlook: Expectations for improved performance in the second half of 2026 as historical renewal cycles return.
• Life Sciences Transition: The ongoing shift from transactional to subscription models is progressing, but remains a work in progress.

This earnings call reflects Clarivate's solid start to 2026, with a focus on strategic execution and innovation, although challenges remain in certain segments and competitive pressures are increasing.